A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer

[1]  T. Yamanaka,et al.  S-1 Plus Cisplatin with Concurrent Radiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Multi-Institutional Phase II Trial (West Japan Thoracic Oncology Group 3706) , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  N. Saijo,et al.  4001 ORAL Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients With Locally Advanced Non-small Cell Lung Cancer – a Phase III Trial of the Japan Clinical Oncology Group (JCOG0301) , 2011 .

[3]  M. Edelman,et al.  Population-Based Estimates of Survival Benefit Associated with Combined Modality Therapy in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  F. Nakagawa,et al.  Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. , 2010, Oncology reports.

[5]  A. Ohtsu,et al.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. , 2009, The Lancet. Oncology.

[6]  M. Endo,et al.  Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer , 2009, British Journal of Cancer.

[7]  M. Fukuoka,et al.  S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. , 2009, Clinical lung cancer.

[8]  M. Hiraoka,et al.  TS‐1 enhances the effect of radiotherapy by suppressing radiation‐induced hypoxia‐inducible factor‐1 activation and inducing endothelial cell apoptosis , 2008, Cancer science.

[9]  R. Govindan,et al.  Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Randall K Ten Haken,et al.  Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. , 2006, International journal of radiation oncology, biology, physics.

[11]  A. Kida,et al.  Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer , 2005, British Journal of Cancer.

[12]  N. Saijo,et al.  Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). , 2005, Japanese journal of clinical oncology.

[13]  Michael Lock,et al.  Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  J. Jett,et al.  The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Kudoh,et al.  Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer , 2001, British Journal of Cancer.

[16]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[17]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[18]  K. Kiura,et al.  A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer. , 2011, Lung cancer.

[19]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[20]  W. Sause,et al.  The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. , 1999, International journal of radiation oncology, biology, physics.